Hematology Lab- Pratt
Dr. Pratt’s laboratory employs a multidisciplinary approach to studies at the interface between blood coagulation, inflammation and immunology. Early work consisted of molecular modeling and x-ray crystallographic studies, including high-resolution crystal structures that elucidated the mechanism of fibrin polymerization. She has studied the structure, function and immunogenicity of blood coagulation factor VIII (FVIII) for over 20 years. Her studies of alloimmune responses to FVIII encompass structure/function studies, investigations of cellular immune responses to FVIII, mapping of T-cell and B-cell epitopes, RNASeq/transcriptomics and TCR repertoire analysis of PBMCs and specific lymphocyte populations, and characterization of T-cell clones and polyclonal lines from patients as well as hemophilic mice.
Recent work has included analysis of the national “My Life Our Future” database, which revealed that African American and Hispanic patients have a higher risk of developing neutralizing anti-FVIII antibodies; we also identified both risk-associated and protective HLA haplotypes and are currently conducting a GWAS analysis of whole genome sequences from these participants.
Other current projects include:
- the development of novel resuscitation fluids containing platelets engineered to express supra-physiological levels of clotting or anti-fibrinolytic proteins
- analysis of serial blood samples from patients undergoing extracorporeal membrane oxygenation (ECMO) and development of algorithms to predict their risk of bleeding or thrombosis
- analysis of blood samples from long-COVID subjects to evaluate potential indicators of immunothrombosis risk
- analysis of blood samples from a porcine model to help evaluate next-generation ECMO devices
- development and use of “blood vessel on a chip” devices to evaluate platelet plug formation and coagulation following acute radiation injury, with and without addition of synthetic platelet-like particles
ACTIVE GRANTS
- MDO-3 grant (USUHS + U Minnesota)
"Engineered Platelets for Improved Efficacy in Staunching Hemorrhagic Bleeds"
Role: MPI (corresponding), with Dr. Mark Osborn (Univ of Minnesota)
1.20 calendar
Direct costs: $1,626,108
Indirect costs: $908,976
Project period: 01/012027-12/31/30
Goal: Engineer red blood cells and platelets to render them less immunogenic, and to utilize platelets as efficient clotting factor delivery vehicles, so these cells can be combined with plasma or other fluids for trauma resuscitation. Platelet production will be scaled using bioreactors.
- DARPA (PI: P. Walker, USUHS Surgery)
"GOLDEVAC IV&V: Independent Verification and Validation (IV&V) of Single-Cannula Intravascular Life Support in a Porcine Model of Combined Pulmonary Contusion (Blunt Thoracic Lung Injury) and Controlled Hemorrhage for the DARPA GOLDEVAC Program"
Role: Co-I
1.2 calendar
(My lab will receive funds for a postdoctoral fellow or research scientist project)
Project period: 08/15/26-08/14/28
Goal: Provide Government IV&V for Phase 2 of the DARPA GOLDEVAC program, evaluating Two Performer Systems in a 48-hour porcine model of lung injury (ARDS) with controlled hemorrhage, producing independent, modeling-grade evidence of physiologic sufficiency, reliability, and safety.
- Maryland Stem Cell Research Fund (MSCRF)
"Engineered iPSC-derived platelets as clotting factor delivery vehicles for trauma resuscitation"
Role: PI
0.6 calendar
Direct costs: $145,592
Indirect costs: $21,839
Project period: 07/01/25-06/30/27
Goal: Engineer platelets to render them less immunogenic, and to utilize platelets as efficient clotting factor delivery vehicles, so these cells can be combined with plasma or other fluids for trauma resuscitation.
- MDO-1 grant (USUHS + U Minnesota)
"Development of an Off the Shelf Erythrocyte-Based Resuscitation Fluid for Hemostasis and Improved Oxygen Delivery"
Role: MPI (corresponding), with Dr. Mark Osborn Univ of Minnesota)
1.20 calendar
Direct costs: $1,831,203
Indirect costs: $177,724
Project period: 09/23/2024-09/22/2028
Goal: Engineer red blood cells and platelets to render them less immunogenic, and to utilize platelets as efficient clotting factor delivery vehicles, so these cells can be combined with plasma or other fluids for trauma resuscitation.
- MDO-2 grant (USUHS + U Minnesota)
"Development of Predictive Algorithms for Patient Bleeding or Clotting During Extracorporeal Membrane Oxygen Support"
Role: PI
1.20 calendar
Direct + indirect costs: $3.855M
Project period: 10/01/2024-09/30/28
Goal: Develop algorithms to predict the risk of serious bleeding while on extracorporeal membrane oxygen support (ECMO) therapy. We will utilize bioinformatics methods to analyze clinical data and serial blood samples collected from subjects receiving ECMO.
- Health Resources and Services Administration (Machin, U. of Pittsburgh)
"The 'INHIBIT' Hemophilia Registry"
Role: PI on scientific subaward
1.20 calendar
Direct costs (subaward): $927,929
Indirect costs: $149,397
Project period: 7/1/2024-6/30/2029
Goal: Characterize human immune responses to a therapeutic FVIII-Fc fusion protein. This subaward is a scientific satellite study to the “INHIBIT” clinical trial, PI Nicoletta Machin, DO, UPitt.
- Armed Forces Institute for Regenerative Medicine (AFIRM) (PI: R. Day, USUHS Dept. Pharmacology)
"On-demand Synthetic Platelet technology for Radiation-induced EmergencY (OSPREY)"
Role: Co-I (pending)
1.2 calendar (My lab will receive funds for a postdoctoral fellow or research scientist project)
Project period: TBD
Goal: Evaluate the effect of a synthetic platelet analog product, “Synthoplate”, as a potential off-the-shelf therapeutic to restore hemostasis following acute radiation injury. The project will employ murine and NHP models, blood from healthy human donors, and endothelial “organ-on-a-chip” models.